19:20 , May 1, 2018 |  BC Extra  |  Company News

EC approves BioCryst's Alpivab for influenza

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said the European Commission approved an MAA for Alpivab peramivir to treat uncomplicated influenza in patients at least two years old. The injectable formulation of a viral neuraminidase inhibitor is approved...
22:43 , Mar 1, 2018 |  BC Week In Review  |  Clinical News

CHMP backs approval of BioCryst's Alpivab

EMA's CHMP recommended approval of Alpivab peramivir from BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to treat uncomplicated influenza. The injectable formulation of viral neuraminidase inhibitor is approved in the U.S. as Rapivab. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C.  Product:...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Trapping influenza neuraminidase

Researchers at The University of British Columbia have used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase that could have activity against flu strains resistant to marketed inhibitors of the target.1 The...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Influenza virus neuraminidase In vitro, cell culture and mouse studies suggest covalent neuraminidase inhibitors...
07:00 , Sep 7, 1999 |  BioCentury  |  Tools & Techniques

Why Relenza was approved

A recent FDA memorandum provides insight into the agency's thinking when it approved Biota Holdings Ltd.'s Relenza zanamivir dry powder for inhalation to treat influenza A and B - despite a 14-4 advisory committee vote...